Pegsunercept

Pegsunercept
Clinical data
Routes of; administration	subcutaneous injection
ATC code	none;
Legal status
Legal status	investigational;
Pharmacokinetic data
Bioavailability	N/A
Identifiers
CAS Number	330988-75-5 ;
ChemSpider	none;
UNII	Q5I7SFZ853;
KEGG	D05393 ;
Chemical and physical data
Formula	C502H758N154O165S16
Molar mass	12,103 g/mol (protein part) g·mol−1
	(what is this?)

Pegsunercept is a drug for the treatment of rheumatoid arthritis. As of January 2010, Phase II clinical trials have been completed.^[1]^[2]^[3] It is being developed by Amgen.

Similarly to etanercept, pegsunercept is a soluble tumor necrosis factor receptor. Pegsunercept is a PEGylated protein.^[3]

References[]

^ Clinical trial number NCT00037700 for "Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis" at ClinicalTrials.gov
^ Clinical trial number NCT00111423 for "Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)" at ClinicalTrials.gov
^ Jump up to: ^a ^b Furst DE, Fleischmann R, Kopp E, Schiff M, Edwards C, Solinger A, Macri M (December 2005). "A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis". The Journal of Rheumatology. 32 (12): 2303–10. PMID 16331754.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by .

[1] Clinical trial number NCT00037700 for "Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis" at ClinicalTrials.gov

[2] Clinical trial number NCT00111423 for "Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)" at ClinicalTrials.gov

[Furst-3] Jump up to: ^a ^b Furst DE, Fleischmann R, Kopp E, Schiff M, Edwards C, Solinger A, Macri M (December 2005). "A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis". The Journal of Rheumatology. 32 (12): 2303–10. PMID 16331754.

[1]

[2]

[3]

Clinical data
Routes of administration	subcutaneous injection
ATC code	none
Legal status
Legal status	investigational
Pharmacokinetic data
Bioavailability	N/A
Identifiers
CAS Number	330988-75-5^N
ChemSpider	none
UNII	Q5I7SFZ853
KEGG	D05393^Y
Chemical and physical data
Formula	C₅₀₂H₇₅₈N₁₅₄O₁₆₅S₁₆
Molar mass	12,103 g/mol (protein part) g·mol⁻¹
^NY (what is this?)